Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy

Background: Immune checkpoint inhibitors (ICIs) are approved as cancer immunotherapeutic agents for advanced malignant melanoma (MM) in recent years, and nivolumab and ipilimumab are the most widely used ICIs either alone or in combination. However, their efficacy and safety between single and combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pradeep, Jnaneshwari, Win, Thin Thin, Aye, Saint Nway, Sreeramareddy, Chandrashekhar T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414012/
https://www.ncbi.nlm.nih.gov/pubmed/36046644
http://dx.doi.org/10.7150/jca.72210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414012/
https://www.ncbi.nlm.nih.gov/pubmed/36046644
http://dx.doi.org/10.7150/jca.72210

Ejemplares similares